JPM26: Leo Pharma’s growth strategy puts a spotlight on rare dermatology diseases
Leo Pharma’s bold commitment to be a strong player in the dermatological space was made clear at the J.P Morgan …
Post
-
-
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death
Intellia Therapeutics is confident in the safety profile of its gene therapies after revealing that a man's death in a …
-
JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus
At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in …
-
FDA and EMA release collaborative AI framework for drug development
In a bid to optimise the use of AI in drug development, US and European regulators have banded together to …
-
New study finds stroke associated with poor glycemic control in diabetics
Diabetes mellitus is a common disease that affects how the body uses blood sugar and can lead to excess glucose …
-
From Fragmented to Unified: How Flex Databases Is Rewiring Clinical Operations for the AI Era
With pressure mounting to shorten timelines and tighten oversight, Flex Databases is betting on a single, configurable eClinical platform to …
-
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
ImmunityBio’s immunotherapy drug Anktiva (nogapendekin alfa inbakicept) has shown success in combination with a checkpoint inhibitor in two non-small cell …
-
Akeso’s PD-1/CTLA-4 bispecific trumps chemo in frontline gastric cancer
Akeso’s cadonilimab has outperformed the activity of the current standard of care (SoC) treatment option during a real-world study in …
-
JPM26: Sanofi’s COAST 1 clinical trials exhibit positive results, with researchers optimistic for COAST 2 results for amlitelimab
Sanofi is excited for 2026. At the JP Morgan Healthcare conference, several upcoming catalyst events were highlighted, including high-profile read-outs, …
-
JPM26: 2025 a “breakout year” for rare disease biotechs
Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies …
-
JPM26: BioNTech gears up for multiproduct oncology status by 2030
BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines. Speaking …
-
JPM26: Amgen touts MariTide’s weight loss, T2D potential off Phase II data
Amgen’s obesity and type 2 diabetes (T2D) hopeful, MariTide (maridebart cafraglutide), has demonstrated its once-quarterly dosing potential in a mid-stage …
-
Marea reports positive Phase I results for MAR002 trial in acromegaly
Marea Therapeutics has announced positive top line results from its first-in-human Phase I study of MAR002, an allosteric monoclonal antibody …
-
AbCellera begins Phase II ABCL635 trial for menopause-related VMS
AbCellera has dosed the first patient in the Phase II portion of its ongoing Phase I/II clinical trial evaluating ABCL635 …
-
JPM26: Roche’s rejuvenation strategy for the oncology and haematology portfolio
At the J.P. Morgan Healthcare Conference 2026, Roche Pharma’s CEO, Teresa Graham, shared the company’s vision for the next few …
